A systematic review of health-related quality of life in cutaneous melanoma

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Cornish, D ^a   Holterhues, C ^a   van de Poll Franse, L V ^b,c   Coebergh, J W ^a,b   Nijsten, T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b The Netherlands   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

Author keywords

Cutaneous; Health status; Health status indicators; Melanoma; Quality of life (QOL); Skin; Survival analysis

Indexed keywords

HUMAN; MELANOMA; METASTASIS; PATHOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SKIN TUMOR;

HUMANS; MELANOMA; QUALITY OF LIFE; SKIN NEOPLASMS;

EID: 70349570445     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp255     Document Type: Article

References (26)

1. de Vries E, Houterman S, Janssen-Heijnen ML et al. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the southeast of The Netherlands. Ann Oncol 2007; 18: 1110-1116.
2. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-126.
3. Karim-Kos HE, de Vries E, Soerjomataram I et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-1389.
4. Stam-Posthuma JJ, van Duinen C, Scheffer E et al. Multiple primary melanomas. J Am Acad Dermatol 2001; 44: 22-27.
5. De Vries E, Dore JF, Autier P et al. Patients' perception of the cause of their melanoma differs from that of epidemiologists. Br J Dermatol 2002; 147: 388-389.
6. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6: 608-621.
7. Mols F, Vingerhoets AJ, Coebergh JW, van de Poll-Franse LV. Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer 2005; 41: 2613-2619.
8. Cormier JN, Ross MI, Gershenwald JE et al. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer 2008; 112: 2249-2257.
9. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-1125.
10. Lehto US, Ojanen M, Dyba T et al. Baseline psychosocial predictors of survival in localized melanoma. J Psychosom Res 2007; 63: 9-15.
11. Dixon S, Walters SJ, Turner L, Hancock BW. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006; 94: 492-498.
12. Rataj D, Jankowiak B, Krajewska-Kulak E et al. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients. Cancer Nurs 2005; 28: 172-178.
13. Lehto US, Ojanen M, Kellokumpu-Lehtinen P. Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol 2005; 16: 805-816.
14. Al-Shakhli H, Harcourt D, Kenealy J. Psychological distress surrounding diagnosis of malignant and nonmalignant skin lesions at a pigmented lesion clinic. J Plast Reconstr Aesthet Surg 2006; 59: 479-486.
15. Trask PC, Griffith KA. The identification of empirically derived cancer patient subgroups using psychosocial variables. J Psychosom Res 2004; 57: 287-295.
16. Devine D, Parker PA, Fouladi RT, Cohen L. The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 2003; 12: 453-462.
17. Trask PC, Paterson AG, Griffith KA et al. Cognitive-behavioral intervention for distress in patients with melanoma: comparison with standard medical care and impact on quality of life. Cancer 2003; 98: 854-864.
18. Ko CY, Maggard M, Livingston EH. Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res 2003; 114: 1-5.
19. Trask PC, Paterson AG, Hayasaka S et al. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol 2001; 19: 2844-2850.
20. Cormier JN, Davidson L, Xing Y et al. Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale. J Support Oncol 2005; 3: 139-145.
21. Boyle DA. Psychological adjustment to the melanoma experience. Semin Oncol Nurs 2003; 19: 70-77.
22. Newton-Bishop JA, Nolan C, Turner F et al. A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc 2004; 9: 152-159.
23. Both H, Essink-Bot ML, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127: 2726-2739.
24. Crott R. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics 2004; 22: 569-580.
25. Boesen EH, Boesen SH, Frederiksen K et al. Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2007; 25: 5698-5703.
26. Fawzy FI, Fawzy NW, Hyun CS et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993; 50: 681-689.